Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1225-1231

  Park, Cheol ^a   Kim, Gi Young ^a   Kim, Gun Do ^b   Choi, Byung Tae ^c   Park, Yeong Min ^d,e   Choi, Yung Hyun ^a,e  

^a Dong Eui University   (South Korea)

^b Dong Eui University   (South Korea)

^c Jeju National University   (South Korea)

^d Kukyong National University   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

Author keywords

COX 2; Curcumin; G2 M arrest; p21; T24 bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

ARTICLE; BLADDER TUMOR; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DIVISION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL DIVISION; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; G2 PHASE; HUMANS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33744997200     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1225     Document Type: Article

References (31)

1. Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196, 2001.
2. Cheng T: Cell cycle inhibitors in normal and tumor stem cells. Oncogene 23: 7256-7266, 2004.
3. Lee MH and Yang HY: Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907-1922, 2001.
4. Soh JW and Weinstein IB: Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37: 261-285, 2003.
5. Umar A, Viner JL, Anderson WF and Hawk ET: Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26: S48-S57, 2003. (Pubitemid 36961140)
6. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398, 2003. (Pubitemid 36361976)
7. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223: 181-190, 2005. (Pubitemid 40719616)
8. Chen H, Zhang ZS, Zhang YL and Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 19: 3675-3680, 1999.
9. Moragoda L, Jaszewski R and Majumdar AP: Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 21: 873-878, 2001. (Pubitemid 32494183)
10. Choudhuri T, Pal S, Das T and Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280: 20059-20068, 2005. (Pubitemid 41379535)
11. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M and Aggarwal BB: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852-8861, 2002. (Pubitemid 36132405)
12. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA and Gautam SC: Curcumin (Diferuloyl-Methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2: 95-103, 2003.
13. Lin JK, Pan MH and Lin-Shiau SY: Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 13: 153-158, 2000.
14. Leu TH and Maa MC: The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anti-Cancer Agents 2: 357-370, 2002.
15. Gescher A: Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? J Chemother 16: S3-S6, 2004.
16. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA and Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem 272: 28479-28484, 1997. (Pubitemid 27517796)
17. Ling YH, el-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832-841, 1996.
18. McGowan CH and Russell P: Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 12: 75-85, 1993. (Pubitemid 23042384)
19. Jin P, Gu Y and Morgan DO: Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134: 963-970, 1996. (Pubitemid 26278221)
20. Perdiguero E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 3: 733-737, 2004. (Pubitemid 40187901)
21. El-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer EW, Kinzler KW and Vogelstain B: WAF1, a potential mediator of p53 suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
22. Baus F, Gire V, Fisher D, Piette J and Dulic V: Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J 22: 3992-4002, 2003. (Pubitemid 36975725)
23. Dulic V, Stein GH, Far DF and Reed SI: Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18: 546-557, 1998. (Pubitemid 28021065)
24. WAF1/ CIP1 expression by p53-independent pathways. Oncogene 12: 1557-1564, 1996.
25. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB and Mercer WE: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/marcrophage differentiation. Cancer Res 55: 668-674, 1995.
26. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993. (Pubitemid 24036020)
27. Elledges SJ and Harper JW: Cdk inhibitor: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852, 1994.
28. Hour T, Chen J, Huang CY, Guan JY, Lu SH and Pu YS: Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBP beta expressions and suppressing NF-kappaB activation. Prostate 51: 211-218, 2002. (Pubitemid 34492642)
29. Lee J, Im YH, Jung HH, Kim JH, Park JO, Kim K, Kim WS, Ahn JS, Jung CW, Park YS, Kang WK and Park K: Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. Biochem Biophys Res Commun 334: 313-318, 2005. (Pubitemid 40982371)
30. Plummer S, Holloway K, Manson M, Munks R, Kaptein A, Farrow S and Howells L: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signaling complex, Oncogene 18: 6013-6020, 1999. (Pubitemid 29535013)
31. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K and Dannenberg AJ: Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20: 445-451, 1999. (Pubitemid 29112633)